Baird Maintains Outperform on Alto Neuroscience, Raises Price Target to $41

Baird analyst Brian Skorney has maintained an 'Outperform' rating on Alto Neuroscience (NYSE: ANRO) and raised the price target from $22 to $41. This adjustment reflects a positive outlook on the company's performance.